Nathan Fielder and Lance Oppenheim’s film about disgraced Theranos founder Elizabeth Holmes has earned more than $15 million in ticket sales. The result signals strong audience interest in a genre-bending account of one of the most closely watched corporate scandals.
The film places Holmes and the collapse of Theranos at the center of a story shaped by two filmmakers known for unconventional nonfiction work. Its ticket sales show that viewers remain interested in stories about failed companies, public deception, and the people behind them.
A Corporate Scandal Returns to the Screen
Holmes rose to prominence as the founder of Theranos, a blood-testing company that drew intense public and investor attention. She later became a symbol of failed oversight and unchecked corporate claims.
Fielder and Oppenheim approach that history through a format described as genre-bending. That label suggests the project does not fit neatly into a standard documentary or dramatic film category.
The creative approach may have helped distinguish the movie from earlier coverage of Holmes. Her story has already received wide attention through news reporting and screen productions. A new film therefore faced the challenge of presenting familiar events in a fresh form.
The film “made more than $15 million in ticket sales.”
Ticket Sales Point to Sustained Interest
Crossing $15 million gives the film a clear measure of commercial reach. Ticket revenue alone does not reveal profitability because production, marketing, and distribution costs were not disclosed.
Still, the total suggests that the project reached more than a small group of documentary viewers. It also shows that a film centered on corporate misconduct can compete for public attention through an unusual storytelling style.
- The film was made by Nathan Fielder and Lance Oppenheim.
- It focuses on former Theranos founder Elizabeth Holmes.
- It combines genres rather than following one standard format.
- Ticket sales have exceeded $15 million.
The result may interest studios weighing projects about real people and heavily reported scandals. Familiarity can help attract audiences, but it can also produce fatigue. The filmmakers’ distinct method appears to offer a way around that problem.
Questions About Fact, Performance, and Accountability
A genre-mixing film about a real scandal also creates editorial questions. Viewers must be able to tell which scenes document events, which interpret them, and which use performance or invention.
That distinction matters in a story involving harmed patients, employees, and investors. Creative choices can sharpen public understanding, but they can also shift attention from institutional failures to the personality of a famous founder.
The film’s commercial performance suggests that Holmes remains a major cultural figure after Theranos. Yet the wider significance lies in why her story still sells tickets. It combines ambition, celebrity, money, technology, and failures of scrutiny.
More financial details would be needed to judge the movie’s business success in full. For now, the $15 million total provides firm evidence of audience demand. The next question is whether its genre-bending treatment deepens public understanding of the Theranos scandal, or mainly extends the long-running fascination with Holmes herself.
